These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37263072)

  • 1. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
    Khanna V; Azenkot T; Liu SQ; Gilbert J; Cheung E; Lau K; Pollyea DA; Traer E; Jonas BA; Zhang TY; Mannis GN
    Leuk Res; 2023 Aug; 131():107331. PubMed ID: 37263072
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Management of Acute Myeloid Leukemia: A Review.
    Venugopal S; Sekeres MA
    JAMA Oncol; 2024 Oct; 10(10):1417-1425. PubMed ID: 39115831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
    Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
    J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
    Maiti A; Konopleva MY
    Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.
    Shahswar R; Ganser A
    Expert Rev Hematol; 2024 Oct; 17(10):723-739. PubMed ID: 39246164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
    Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
    Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
    Mei M; Aldoss I; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
    Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
    Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
    Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
    Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Jonas BA; Pollyea DA
    Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Venetoclax: A New Hope for Elderly Patients with Acute Myeloid Leukemia].
    Marques B; Afonso C; Cortesão E
    Acta Med Port; 2023 Jan; 36(1):59-62. PubMed ID: 35348454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
    Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
    Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.